A comprehensive study across multiple cancer types demonstrated that patients with pathogenic or likely pathogenic LRP1B alterations experienced significantly improved outcomes with ICI treatment compared to those with alterations of unknown significance, regardless of their TMB/MSI status (48). This evidence concerns the gene LRP1B and cancer.